FDA 483 - Lupin Limited - December 04, 2018

The FDA conducted an inspection of Lupin Limited (Unit I), an API and Finished Dosage Manufacturer located in Mandideep, Madhya Pradesh, India, from November 26 to December 4, 2018. The inspection, carried out under current Good Manufacturing Practices (cGMP) regulations, resulted in numerous observations detailed in an FDA 483 report, highlighting significant deficiencies across several critical manufacturing and quality control areas. Key issues included inadequate procedures for aseptic process simulations, particularly concerning environmental monitoring, disinfection frequencies, and comprehensive challenging of worst-case conditions. Cleaning validations for aseptic manufacturing equipment were found deficient, lacking scientific support for bioburden testing methods, campaign times, and sampling locations. Environmental monitoring systems and cleaning practices in aseptic areas were also criticized for failing to address out-of-specification microbial counts and ensuring proper control of cleaning materials. Furthermore, the firm demonstrated a failure to thoroughly investigate unexplained discrepancies, such as fungal contamination, product impurities, and numerous market complaints regarding particulate matter in sterile injectables and thickening/dose shortages in oral suspensions. Investigations were not consistently extended to other affected batches, and some products manufactured with compromised raw materials or without complete batch records were released to the U.S. market. Deviations were not adequately recorded, and the firm failed to submit required Field Alert Reports for significant quality issues. A pervasive lack of personnel training, oversight, and scientific understanding of critical quality processes was also noted. Lupin Limited (Unit I) is required to address these observations by conducting thorough investigations, identifying root causes, implementing effective corrective and preventive actions, and submitting a comprehensive response to the FDA within 15 business days.